Parkinson's disease and cancer: Insights for pathogenesis from epidemiology

Annals of the New York Academy of Sciences

Volumn 1155, Issue , 2009, Pages 324-334

  D'Amelio, Marco ^a   Ragonese, Paolo ^a   Sconzo, Gabriella ^a   Aridon, Paolo ^a   Savettieri, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cancer; Epidemiology; Genetics; Parkinson's disease; Risk factors

Indexed keywords

LEVODOPA;

CANCER CELL; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL GROWTH; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENETIC ASSOCIATION; HUMAN; NEOPLASM; PARKINSON DISEASE; PATHOGENESIS; SUBSTANTIA NIGRA;

EID: 61649091807     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2008.03681.x     Document Type: Conference Paper

References (55)

1. Langston, J.W., P. Ballard, J.W. Tetrud & I. Irwin. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 : 979 980.
2. Hernán, M.A., B. Takkouche, F. Caamaño-Isorna & J.J. Gestal-Otero. 2002. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52 : 276 284.
3. Ragonese, P., M. D'Amelio & G. Savettieri. 2006. Implications for estrogens in Parkinson's disease: An epidemiological approach. Ann. N. Y. Acad. Sci. 1089 : 373 382.
4. Ragonese, P., M. D'Amelio, G. Callari, et al. 2006. Age at menopause predicts age at onset of Parkinson's disease. Mov. Disord. 21 : 2211 2214.
5. Ragonese, P., M. D'Amelio, G. Salemi, et al. 2004. Risk of Parkinson disease in women: Effect of reproductive characteristics. Neurology 62 : 2010 2014.
6. de Lau, L.M. & M.M. Breteler. 2006. Epidemiology of Parkinson's disease. Lancet Neurol. 5 : 525 535.
7. Greenamyre, J.T. & T.G. Hastings. 2004. Biomedicine: Parkinson's - divergent causes, convergent mechanisms. Science 304 : 1120 1122.
8. Doshay, L.J. 1954. Problem situations in paralysis agitans. JAMA 156 : 680 684.
9. Hoehn, M.M. & M.D. Yahr. 1967. Parkinsonism: Onset, progression and mortality. Neurology 17 : 427 442.
10. Elbaz, A., B.J. Peterson, P. Yang, et al. 2002. Nonfatal cancer preceding Parkinson's disease: A case-control study. Epidemiology 13 : 157 164.
11. D'Amelio, M., P. Ragonese, L. Morgante, et al. 2004. Tumor diagnosis preceding Parkinson's disease: A case-control study. Mov. Disord. 19 : 807 811.
12. Olsen, J.H., S. Friis & K. Frederiksen. 2006. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17 : 582 587.
13. Driver, J.A., T. Kurth & J.E. Buring. 2007a. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. Cancer Causes Control 18 : 705 711.
14. Jansson, B. & J. Jankovic. 1985. Low cancer rates among patients with Parkinson's disease. Ann. Neurol. 17 : 505 509.
15. Møller, H., L. Mellemkjaer, J.K. McLaughlin, et al. 1995. Occurrence of different cancers in patients with Parkinson's disease. BMJ 310 : 1500 1501.
16. Minami, Y., R. Yamamoto, M. Nishikouri, et al. 2000. Mortality and cancer incidence in patients with Parkinson's disease. J. Neurol. 247 : 429 434.
17. Olsen, J.H., S. Friis & K. Frederiksen. 2005. Atypical cancer pattern in patients with Parkinson's disease. Br. J. Cancer 92 : 201 205.
18. Elbaz, A., Peterson, B.J. Bower & J.H. Yang. 2005. Risk of cancer after the diagnosis of Parkinson's disease: A historical cohort study. Mov. Disord. 20 : 719 725.
19. Driver, J.A., G. Logroscino, J.E. Buring, et al. 2007b. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol. Biomarkers Prev. 16 : 1260 1265.
20. Fortes, C. & E. de Vries. 2008. Nonsolar occupational risk factors for cutaneous melanoma. Int. J. Dermatol. 47 : 319 328.
21. Olsen, J.H., K. Tangerud, L. Wermuth, et al. 2007. Treatment with levodopa and risk for malignant melanoma. Mov. Disord. 22 : 1252 1257.
22. Zanetti, R., S. Rosso & D.I. Loria. 2007. Parkinson's disease and cancer. Cancer Epidemiol. Biomarkers Prev. 16 : 1081.
23. Kawashima, M., S.O. Suzuki, K. Doh-ura, et al. 2000. Acta Neuropathol. (Berl.) 99 : 154 160.
24. Fung, K.M., L.B. Rorke & B. Giasson. 2003. Acta Neuropathol. (Berl.) 106 : 167 175.
25. Bruening, W., B.I. Giasson & A.J. Klein-Szanto. 2000. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88 : 2154 2163.
26. Fujita, M., S. Sugama, M. Nakai, et al. 2007. Alpha-synuclein stimulates differentiation of osteosarcoma cells: Relevance to downregulation of proteasome activity. J. Biol. Chem. 282 : 5736 5748.
27. Lucking, C.B., A. Durr, V. Bonifati, et al. 2000. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342 : 1560 1567.
28. Deng, H., W. Le, Y. Guo, C.B. Hunter, et al. 2006. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch. Neurol. 63 : 273 277.
29. Deng, H., W.D. Le, C.B. Hunter, et al. 2007. A family with Parkinson's disease, essential tremor, Bell's palsy and parkin mutations. Arch. Neurol. 64 : 421 424.
30. Mizuno, Y., N. Hattori, S. Kubo, et al. 2008. Progress in the pathogenesis and genetics of Parkinson's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363 : 2215 2227.
31. Wang, F., S. Denison, J.P. Lai, et al. 2004. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40 : 85 96.
32. Denison, S.R., F. Wang, N.A. Becker, et al. 2003. Alterations in the common fragile site gene parkin in ovarian and other cancers. Oncogene 22 : 8370 8378.
33. Agirre, X., J. Román-Gómez, I. Vázquez, et al. 2006. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int. J. Cancer 118 : 1945 1953.
34. Cesari, R., E.S. Martin, G.A. Calin, et al. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc. Natl. Acad. Sci. USA 100 : 5956 5961.
35. Picchio, M.C., E.S. Martin, R. Cesari, et al. 2004. Alterations of the tumor suppressor gene parkin in non-small cell lung cancer. Clin. Cancer Res. 10 : 2720 2724.
36. Fujiwara, M., H. Marusawa, H.Q. Wang, et al. 2008. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 27 : 6002 6011.
37. Leroy, E., R. Boyer & G. Auburger. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395 : 451 452.
38. Long, E.M. & M.A. Long, et al. 2003. Stimulation of the murine Uchl1 gene promoter by the B-Myb transcription factor. Lung Cancer 42 : 9 21.
39. Okochi-Takada, E., K. Nakazawa, M. Wakabayashi, et al. 2006. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int. J. Cancer 119 : 1338 1344.
40. Mani, A. & E.P. Gelmann. 2005. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 23 : 4776 4789.
41. Zhang, H.G., J. Wang, X. Yang, et al. 2004. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23 : 2009 2015.
42. Bonifati, V. et al. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 : 256 259.
43. Moore, D.J., L. Zhang, J. Troncoso, et al. 2005. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14 : 71 84.
44. Yokota, T., K. Sugawara, K. Ito, et al. 2003. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem. Biophys. Res. Commun. 312 : 1342 1348.
45. Mitsumoto, A., Y. Nakagawa, A. Takeuchi, et al. 2001. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic. Res. 35 : 301 310.
46. Kim, R.H., M. Peters, Y. Jang, et al. 2005. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7 : 263 273.
47. Kim, R.H. & T.W. Mak. 2006. Tumours and tremors: How PTEN regulation underlies both. Br. J. Cancer 94 : 620 624.
48. Le Naour, F., D.E. Misek, M.C. Krause, et al. 2001. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin. Cancer Res. 7 : 3328 3335.
49. MacKeigan, J.P., C.M. Clements, J.D. Lich, et al. 2003. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: Identification of RS/DJ-1 and RhoGDIalpha. Cancer Res. 63 : 6928 6934.
50. Valente, E.M. et al. 2004a. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 : 1158 1160.
51. Valente, E.M. et al. 2004b. PINK1 mutations are associated with sporadic early-onset Parkinsonism. Ann. Neurol. 56 : 336 341.
52. West, A.B., V.L. Dawson & T.M. Dawson. 2005. To die or grow: Parkinson's disease and cancer. Trends Neurosci. 28 : 348 352.
53. Futreal, P.A., L. Coin, M. Marshall, et al. 2004. A census of human cancer genes. Nat. Rev. Cancer 4 : 177 183.
54. Paisan-Ruiz, C. et al. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 : 595 600.
55. Smith, W.W., Z. Pei, H. Jiang, et al. 2006. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9 : 1231 1233.